Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Archives of Gynecology and Obstetrics
Erschienen in: Archives of Gynecology and Obstetrics 3/2015

01.03.2015 | Gynecologic Endocrinology and Reproductive Medicine

Follicular fluid anti-Müllerian hormone: a predictive marker of fertilization capacity of MII oocytes

verfasst von: Tamara Tramišak Milaković, Linda Panić Horvat, Kristina Čavlović, Neda Smiljan Severinski, Hrvoje Vlašić, Ivan Vlastelić, Dejan Ljiljak, Anđelka Radojčić Badovinac

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The present study aimed to correlate anti-Müllerian hormone (AMH) levels in follicular fluid (FF) with oocyte maturity stages, morphological quality of metaphase II (MII) oocyte and fertilization capacity of MII oocytes.

Methods

A total of 92 infertile women undergoing controlled ovarian stimulation and intracytoplasmic sperm injection were analyzed. Patients were divided into two groups according to age: <35 years (n = 43) and ≥35 years (n = 49). An FF sample was obtained from a single dominant follicle in each patient for a total of 92 follicular fluid samples analyzed. AMH levels in serum and follicular fluid were measured by enzyme-linked immunosorbent assay. Mature MII oocytes, zygotes, and embryos were assessed for morphological quality.

Results

Serum AMH levels were significantly higher in patients aged <35 years. No correlation was observed between FF AMH level and oocyte maturation stages or morphological quality of MII oocyte. Significantly lower FF AMH levels were observed in fertilized MII oocytes than in non-fertilized MII oocytes in patients aged <35 years (2.56 ± 2.0 ng/ml vs. 4.81 ± 4.14 ng/ml; p = 0.032).

Conclusions

The present study revealed no correlation between FF AMH and oocyte maturity stage or morphological quality of MII oocyte. However, FF AMH might be a predictive marker for fertilization capacity of MII oocytes.
Literatur
1.
Gilchrist RB, Lane M, Thompson JG (2008) Oocyte-secreted factors: regulators of cumulus cell function and oocyte quality. Hum Reprod Update 14(2):159–177PubMedCrossRef
2.
Balaban B, Urman B (2006) Effect of oocyte morphology on embryo development and implantation. Reprod Biomed Online 12(5):608–615PubMedCrossRef
3.
Ubaldi F, Rienzi L (2008) Morphological selection of gametes. Placenta 1(29):115–120CrossRef
4.
Fortune JE (1994) Ovarian follicular growth and development in mammals. Biol Reprod 50(2):225–232PubMedCrossRef
5.
Revelli A, Delle Piane L, Casano S, Molinari E, Massobrio M, Rinaudo P (2009) Follicular fluide content and oocyte quality: from single biochemical markers to metabolomics. Reprod Biol Endocrinol 7:40PubMedCentralPubMedCrossRef
6.
Veeck L (1990) The morphological assessment of human oocytes and early concepts. Handb Lab Diagn Treat Infertil
7.
Ebner T, Yaman C, Moser M, Sommergruber M, Feichtinger O, Tews G (2000) Prognostic value of first polar body morphology on fertilization rate and embryo quality in intracytoplasmic sperm injection. Hum Reprod 15(2):427–430PubMedCrossRef
8.
Xia P (1997) Intracytoplasmic sperm injection: correlation of oocyte grade based on polar body, perivitelline space and cytoplasmic inclusions with fertilization rate and embryo quality. Hum Reprod 12(8):1750–1755PubMedCrossRef
9.
Rienzi L, Vajta G, Ubaldi F (2011) Predictive value of oocyte morphology in human IVF: a systematic review of the literature. Hum Reprod Update 17(1):34–45PubMedCentralPubMedCrossRef
10.
Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB (2006) A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update 12:685–718PubMedCrossRef
11.
Broer SL, Mol BWJ, Hendriks D, Broekmans FJM (2009) The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertil Steril 91(3):705–714PubMedCrossRef
12.
Nelson SM, Yates RW, Fleming R (2007) Serum anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles—implications for individualization of therapy. Hum Reprod 22(9):2414–2421PubMedCrossRef
13.
Wunder DM, Guibourdenche J, Birkhäuser MH, Bersinger NA (2008) Anti-Müllerian hormone and inhibin B as predictors of pregnancy after treatment by in vitro fertilization/intracytoplasmic sperm injection. Fertil Steril 90(6):2203–2210PubMedCrossRef
14.
Broer SL, van Disseldorp J, Broeze KA, Dolleman M, Opmeer BC, Bossuyt P et al (2013) Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Hum Reprod Update 19(1):26–36PubMedCrossRef
15.
Ebner T, Sommergruber M, Moser M, Shebl O, Schreier-Lechner E, Tews G (2006) Basal level of anti-Mullerian hormone is associated with oocyte quality in stimulated cycles. Hum Reprod 21:2022–2026PubMedCrossRef
16.
Irez T, Ocal P, Guralp O, Cetin M, Aydogan B, Sahmay S (2011) Different serum anti-Müllerian hormone concentrations are associated with oocyte quality, embryo development parameters and IVF-ICSI outcomes. Arch Gynecol Obstet 284(5):1295–1301PubMedCrossRef
17.
Lekamge DN, Barry M, Kolo M, Lane M, Gilchrist RB, Tremellen KP (2007) Anti-Müllerian hormone as a predictor of IVF outcome. Reprod Biomed Online 14(5):602–610PubMedCrossRef
18.
Majumder K, Gelbaya TA, Laing I, Nardo LG (2010) The use of anti-Mullerian hormone and antral follicle count to predict the potential of oocytes and embryos. Eur J Obstet Gynecol Reprod Biol 150:166–170PubMedCrossRef
19.
Silberstein T, MacLaughlin DT, Shai I, Trimarchi JR, Lambert-Messerlian G, Seifer DB et al (2006) Müllerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology. Hum Reprod 21(1):159–163PubMedCrossRef
20.
Lin W-Q, Yao L-N, Zhang D-X, Zhang W, Yang X-J, Yu R (2013) The predictive value of anti-mullerian hormone on embryo quality, blastocyst development, and pregnancy rate following in vitro fertilization-embryo transfer (IVF-ET). J Assist Reprod Genet 30(5):649–655PubMedCentralPubMedCrossRef
21.
Sills ES, Collins G, Brady A, Walsh D, Marron K, Peck A et al (2011) Bivariate analysis of basal serum anti-Mullerian hormone measurements and human blastocyst development after IVF. Reprod Biol Endocrinol 9(1):153PubMedCentralPubMedCrossRef
22.
Smeenk JMJ, Sweep FCGJ, Zielhuis GA, Kremer JAM, Thomas CMG, Braat DDM (2007) Antimüllerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracyoplasmic sperm injection. Fertil Steril 87(1):223–226PubMedCrossRef
23.
Fong SL, Baart E, Martini E, Schipper I, Visser J, Themmen A et al (2008) Anti-Müllerian hormone: a marker for oocyte quantity, oocyte quality and embryo quality? Reprod Biomed Online 16(5):664–670CrossRef
24.
Guerif F, Lemseffer M, Couet M-L, Gervereau O, Ract V, Royere D (2009) Serum antimullerian hormone is not predictive of oocyte quality in vitro fertilization. Ann Endocrinol 70(4):230–234CrossRef
25.
Anckaert E, Smitz J, Schiettecatte J, Klein MB, Arce J-C (2012) The value of anti-Mullerian hormone measurement in the long GnRH agonist protocol: association with ovarian response and gonadotrophin dose adjustments. Hum Reprod 27:1829–1839PubMedCentralPubMedCrossRef
26.
Aflatoonian A, Mashayekhy M, Mohamadian F, Mansoori Moghaddam F (2010) The correlation between follicular fluid anti-mullerian hormone levels and fertilization and embryo quality in ART cycles. Iran. J Reprod Med 8(4):157–160
27.
Cupisti S, Dittrich R, Mueller A, Strick R, Stiegler E, Binder H et al (2007) Correlations between anti-Mullerian hormone, inhibin B, and activin A in follicular fluid in IVF/ICSI patients for assessing the maturation and developmental potential of oocytes. Eur J Med Res 12:604–608PubMed
28.
Fanchin R, Mendez Lozano DH, Frydman N, Gougeon A, di Clemente N, Frydman R et al (2007) Anti-Müllerian hormone concentrations in the follicular fluid of the preovulatory follicle are predictive of the implantation potential of the ensuing embryo obtained by in vitro fertilization. J Clin Endocrinol Metab 92(5):1796–1802PubMedCrossRef
29.
Jančar N, Virant-Klun I, Vrtačnik Bokal E (2009) Serum and follicular endocrine profile is different in modified natural cycles than in cycles stimulated with gonadotropin and gonadotropin-releasing hormone antagonist. Fertil Steril 92(6):3
30.
Mehta B, Chimote M, Chimote N, Nath N, Chimote N (2013) Follicular-fluid anti-Mullerian hormone (FF AMH) is a plausible biochemical indicator of functional viability of oocyte in conventional in vitro fertilization (IVF) cycles. J Hum Reprod Sci 6(2):99–105PubMedCentralPubMedCrossRef
31.
Takahashi C, Fujito A, Kazuka M, Sugiyama R, Ito H, Isaka K (2008) Anti-Müllerian hormone substance from follicular fluid is positively associated with success in oocyte fertilization during in vitro fertilization. Fertil Steril 89(3):586–591PubMedCrossRef
32.
Kedem-Dickman A, Maman E, Yung Y, Yerushalmi GM, Hemi R, Hanochi M et al (2012) Anti-Müllerian hormone is highly expressed and secreted from cumulus granulosa cells of stimulated preovulatory immature and atretic oocytes. Reprod Biomed Online 24(5):540–546PubMedCrossRef
33.
Palermo G, Joris H, Devroey P, Van Steirteghem AC (1992) Pregnancies after intracytoplasmic injection of single spermatozoon into an oocyte. Orig Publ 340(8810):17–18
34.
Balaban B, Ata B, Isiklar A, Yakin K, Urman B (2008) Severe cytoplasmic abnormalities of the oocyte decrease cryosurvival and subsequent embryonic development of cryopreserved embryos. Hum Reprod 23(8):1778–1785PubMedCrossRef
35.
Ebner T, Moser M, Sommergruber M, Tews G (2003) Selection based on morphological assessment of oocytes and embryos at different stages of preimplantation development: a review. Hum Reprod Update 9(3):251–262PubMedCrossRef
36.
Rienzi L, Ubaldi FM, Iacobelli M, Minasi MG, Romano S, Ferrero S et al (2008) Significance of metaphase II human oocyte morphology on ICSI outcome. Fertil Steril 90(5):1692–1700PubMedCrossRef
37.
Wilding M, Matteo L, D’Andretti S, Montanaro N, Capobianco C, Dale B (2007) An oocyte score for use in assisted reproduction. J Assist Reprod Genet 24(8):350–358PubMedCentralPubMedCrossRef
38.
Scott L, Alvero R, Leondires M, Miller B (2000) The morphology of human pronuclear embryos is positively related to blastocyst development and implantation. Hum Reprod 15(11):2394–2403PubMedCrossRef
39.
Tesarik J, Greco E (1999) The probability of abnormal preimplantation development can be predicted by a single static observation on pronuclear stage morphology. Hum Reprod 14(5):1318–1323PubMedCrossRef
40.
Zollner U, Zollner K-P, Hartl G, Dietl J, Steck T (2002) The use of a detailed zygote score after IVF/ICSI to obtain good quality blastocysts: the German experience. Hum Reprod 17(5):1327–1333PubMedCrossRef
41.
Hardarson T, Hanson C, Sjögren A, Lundin K (2001) Human embryos with unevenly sized blastomeres have lower pregnancy and implantation rates: indications for aneuploidy and multinucleation. Hum Reprod 16(2):313–318PubMedCrossRef
42.
Van Royen E, Mangelschots K, De Neubourg D, Valkenburg M, Van de Meerssche M, Ryckaert G et al (1999) Characterization of a top quality embryo, a step towards single-embryo transfer. Hum Reprod 14(9):2345–2349PubMedCrossRef
43.
Battaglia DE, Goodwin P, Klein NA, Soules MR (1996) Fertilization and early embryology: influence of maternal age on meiotic spindle assembly oocytes from naturally cycling women. Hum Reprod 11(10):2217–2222PubMedCrossRef
44.
Van Rooij IA, Broekmans FJ, Scheffer GJ, Looman CW, Habbema JD, de Jong FH et al (2005) Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril 83:979–987PubMedCrossRef
45.
La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC et al (2010) Anti-Müllerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 16(2):113–130PubMedCrossRef
46.
Broer SL, Mol B, Dólleman M, Fauser BC, Broekmans FJ (2010) The role of anti-Mullerian hormone assessment in assisted reproductive technology outcome. Curr Opin Obstet Gynecol 22(3):193–201PubMedCrossRef
47.
La Marca A, Papaleo E, D’Ippolito G, Grisendi V, Argento C, Volpe A (2011) The ovarian follicular pool and reproductive outcome in women. Gynecol Endocrinol 28(3):166–169PubMedCrossRef
48.
Anckaert E, Smitz J, Schiettecatte J, Klein BM, Arce J-C (2012) The value of anti-Müllerian hormone measurement in the long GnRH agonist protocol: association with ovarian response and gonadotrophin-dose adjustments. Hum Reprod 27(6):1829–1839PubMedCentralPubMedCrossRef
49.
Salmon NA, Handyside AH, Joyce IM (2004) Oocyte regulation of anti-Müllerian hormone expression in granulosa cells during ovarian follicle development in mice. Dev Biol 266(1):201–208PubMedCrossRef
50.
von Wolff M, Kollmann Z, Flück CE, Stute P, Marti U, Weiss B, Bersinger NA (2014) Gonadotrophin stimulation for in vitro fertilization significantly alters the hormone mileu in follicular fluid: a comparative study between natural cycle IVF and conventional IVF. Hum Reprod 29(5):1049–1057CrossRef
Metadaten
Titel
Follicular fluid anti-Müllerian hormone: a predictive marker of fertilization capacity of MII oocytes
verfasst von
Tamara Tramišak Milaković
Linda Panić Horvat
Kristina Čavlović
Neda Smiljan Severinski
Hrvoje Vlašić
Ivan Vlastelić
Dejan Ljiljak
Anđelka Radojčić Badovinac
Publikationsdatum
01.03.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 3/2015
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-014-3460-9

Weitere Artikel der Ausgabe 3/2015

Archives of Gynecology and Obstetrics 3/2015 Zur Ausgabe

Maternal-Fetal Medicine

The influence of visual impairment on pregnancy outcomes

Gynecologic Oncology

Success rate and safety of tumor debulking with diaphragmatic surgery for advanced epithelial ovarian cancer and peritoneal cancer

General Gynecology

Functional outcome after pelvic floor reconstructive surgery with or without concomitant hysterectomy

Reply

Response to: Impact of luteal phase hysteroscopy and concurrent endometrial biopsy on subsequent IVF cycle outcome

General Gynecology

Polymicrobial Gardnerella biofilm resists repeated intravaginal antiseptic treatment in a subset of women with bacterial vaginosis: a preliminary report

Maternal-Fetal Medicine

The relationship between the VEGF/sVEGFR-1 ratio and threatened abortion

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Gestationsdiabetes: In der zweiten Schwangerschaft folgenreicher als in der ersten

13.05.2024 Gestationsdiabetes Nachrichten

Das Risiko, nach einem Gestationsdiabetes einen Typ-2-Diabetes zu entwickeln, hängt nicht nur von der Zahl, sondern auch von der Reihenfolge der betroffenen Schwangerschaften ab.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise